# Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

> **NCT00295503** · PHASE2 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 53 (actual)

## Conditions studied

- Mesothelioma

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** cisplatin
- **DRUG:** pemetrexed

## Key facts

- **NCT ID:** NCT00295503
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2010-06
- **Final completion:** 2010-08
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2020-10-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00295503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00295503, "Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00295503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*